


The invention is concerned with novel compounds of the formula:



5 wherein the C₇-C₈ bond is a double bond or triple bond; R₁ and R₂ are independently halogen or lower alkyl when the C₇-C₈ bond is a double bond or R₁ and R₂ are independently lower alkyl when the C₇-C₈ bond is a triple bond; or R₁ and R₂ taken together are C₃-₁₃-alkylene in which one carbon atom may be substituted by a heteroatom selected from the group consisting of sulfur, oxygen and nitrogen; or R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring having from 5-6 carbon atoms or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur and the remaining atoms of R₁ and R₂ are carbon; and the pharmaceutically acceptable salts, esters and amides.

20 When R₁ and R₂ taken together are C₃-₁₃-alkylene, it is preferred that they are C₃-₆-alkylene, especially C₆-alkylene. When R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring, the preferred aromatic rings are thiophene, benzene and pyridine. R₁ and R₂ halogens may be Cl, Br, F, or I, with Br and I being preferred. R₁ and R₂ lower alkyl is C₁-₄-alkyl, which may be either straight-chained or branched. The preferred lower alkyl group is methyl.

30 Preferred compounds of the invention are compounds of the formula I wherein the C₇-C₈ bond is a double bond, R₁ and R₂ are independently halogen or lower alkyl, or R₁ and R₂ taken together



are C₃₋₁₃-alkylene in which one carbon atom may be substituted by a heteroatom selected from the group consisting of sulfur, oxygen and nitrogen, or R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring having from 5-6 carbon atoms
5 or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur and the remaining atoms of R₁ and R₂ are carbon, and the pharmaceutically acceptable salts, esters and amides.

10 In another aspect the invention is concerned with compounds of formula I wherein the C₇-C₈ bond is a triple bond R₁ and R₂ are independently lower alkyl, or R₁ and R₂ taken together are C₃₋₁₃-alkylene in which one carbon atom may be substituted by a
15 heteroatom selected from the group consisting of sulfur, oxygen and nitrogen, or R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring having from 5-6 carbon atoms or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur and the remaining atoms of R₁ and R₂ are carbon,
20 and the pharmaceutically acceptable salts, esters and amides.

Retinoic acids function through binding to a family of proteins known as the nuclear retinoic acid receptor ("RAR"). Three members of this family are designated RAR α , RAR β and RAR γ . 9-cis retinoic acid
25 binds to a group of receptors known as the retinoic acid X receptors ("RXR") (Levin et al., Nature, 355:359-361 (1992); Heyman et al., Cell, 68:397-406 (1992)), while all-trans- and 13-cis-retinoic acid, which bind to RAR α , do not. However, 9-cis retinoic acid also acts as a ligand for the RAR group of receptors, and therefore may display the
30 undesirable side effects of all-trans and 13-cis retinoic acid. Both RAR and RXR receptors are known to form heterodimers to mediate their biological functions (Leid et al., Cell, 68:377-395 (1992); Yu et al., Cell, 67:1251-1266 (1991); Zhang et al., Nature, 355:441-446 (1992)).

35 The compounds of the invention demonstrate a high degree of selectivity toward the RXR family of receptors, and are useful as antiproliferative agents and have utility for dermatological and oncological indications. In particular, the compounds of the invention



inhibit the proliferation of sebocytes. Proliferation of sebocytes is known to be a cause of acne. Therefore, inhibiting of the proliferation of sebocytes is a known means of treating acne, and so the compounds of the invention are useful for the treatment of acne.

5

Additionally, the RXR-selective compounds of the invention, at doses at which they are inactive by themselves, increase the activity of retinoids which are useful for the treatment of cancer, especially leukemia and solid tumors, especially head, neck and breast tumors
10 among solid tumors, most especially breast tumors, and are also useful, in themselves, for the treatment of dermatological conditions, especially acne and sun-damaged skin, with reduced toxic effects in comparison to 9-cis- or 13-cis retinoic acid. Retinoids having RAR α activity such as all-trans retinoic acid and 13-cis retinoic acid are
15 compounds which have a biological activity which is based upon their binding to and transactivating RAR α receptors. Thus, the compounds of the invention have utility as potentiators of the activity retinoids having RAR α activity in treating indications where such retinoids are known to be useful. The administration of the compounds of the
20 invention in combination with a retinoid having RAR α activity allows the use of much lower doses of the retinoid, or increases the potency of the retinoid at the usual dose, for any such indications in which such a retinoid having RAR α activity is known to be useful.


25 Thus, the invention further comprises a method of potentiating the activity of retinoids having RAR α activity wherein an amount of a compound of the invention which is effective to potentiate the activity of a compound having RAR α activity (preferably from 1 to 10 times the amount by weight of the compound having RAR α activity) is
30 administered to a patient in conjunction with an effective amount of the compound having RAR α activity. By "in conjunction with" is meant that the RXR-selective compound of the invention may be administered as a series with the compound having RAR α activity, either essentially simultaneously, preferably, but not necessarily,
35 combined together in a single, oral unit dosage form, or at a time prior or subsequent to the administration of the compound having RAR α activity, so that the RXR-selective compound and the compound having RAR α activity are simultaneously present in the blood stream



of the patient so that the RXR-selective compound of the invention is present at a concentration which will potentiate the activity of the compound having RAR α activity. Preferably the RXR-selective compound of the invention and the compound having RAR α activity
5 are administered no longer than four hours apart, more preferably no longer than one hour apart, and most preferably at essentially the same time.

In accordance with this invention, it has been found that the
10 compounds of the invention potentiate the activity of retinoids having RAR α activity in producing differentiation of human leukemia cells in a standard cell culture assay. Thus, the compounds of the invention have an activity which would potentiate the known activity of retinoids having RAR α activity in producing regression or remission of
15 hematological tumors, especially those tumors associated with acute promyelocytic leukemia. This treatment of leukemia would be accomplished by administering a compound of the invention systemically to a patient in conjunction with a retinoid having RAR α activity which is known to be useful for retarding the progression or
20 producing a regression of the hematological tumors. The amount will be dependent on the amount and size of the tumors and on the requirements of the patient.

Also in accordance with this invention, it has been found that
25 the compounds of the invention potentiate the activity of retinoids having RAR α activity in producing regression or remission of solid tumors, especially those tumors associated with the head and neck, and with breast cancer. Thus, the compounds of the invention have an activity which would potentiate the known activity of retinoids having
30 RAR α activity in producing regression or remission of solid tumors, especially those tumors associated with head and neck cancer, and with breast cancer. This treatment of solid tumors would be accomplished by administering a compound of the invention systemically to a patient in conjunction with a retinoid having RAR α
35 activity having activity in producing regression or remission of solid tumors, especially of the head, neck, and breast. The amount will be dependent on the amount and size of the tumors and on the requirements of the patient.



For the treatments given above, the compound of the invention is administered systemically as a composition containing the compound of the invention, optionally in combination with a
5 compound having RAR α activity, and a pharmaceutically acceptable carrier compatible with said compound(s). In preparing such composition, any conventional pharmaceutically acceptable carrier can be utilized. When the drug is administered orally, it is generally administered at regular intervals, conveniently at mealtimes or once
10 daily.

The pharmaceutically acceptable salts include any salt chemically permissible in the art for retinoic acid and applicable to human patients in a pharmaceutically acceptable preparation. Any
15 such conventional pharmaceutically acceptable salt of the compounds of the invention can be utilized. Among the conventional salts which can be utilized there are the base salts included, for example, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium, and ammonium or alkyl ammonium
20 salts.

In accordance with this invention the compounds of the invention can be administered in the form of its pharmaceutically acceptable hydrolyzable esters. Any pharmaceutically acceptable
25 hydrolyzable ester can be used in the compositions and methods of this invention. Among the esters are the aromatic esters such as benzyl (OBzl) or benzyl substituted with lower alkyl, halo, nitro, thio, or substituted thio, i.e., lower alkyl, t-butyl, cyclopentyl, cyclohexyl, cycloheptyl, and 9-fluorenylmethyl.


30 The pharmaceutical compositions can be made up in any conventional form including: (a) a solid form for oral administration such as tablets, capsules, pills, powders, granules, and the like; and (b) preparations for topical administration such as solutions, suspensions,
35 ointments, creams, gels, micronized powders, aerosols and the like. The pharmaceutical compositions may be sterilized and/or may contain adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure, and/or buffers.



In accordance with this invention, the aforementioned compounds of the invention are useful in pharmaceutically acceptable oral modes. These pharmaceutical compositions of the invention
5 contain said compound of the invention or its pharmaceutically acceptable salts and its pharmaceutically acceptable hydrolyzable esters in association with a compatible pharmaceutically acceptable carrier material. Any conventional carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier
10 material suitable for oral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceutical preparations may contain other pharmaceutically active agents, preferably a retinoid having $RAR\alpha$
15 activity. Additional additives such as flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.

The pharmaceutical preparations can be made up in any
20 conventional oral dosage form including a solid form for oral administration such as tablets, capsules, pills, powders, granules, and the like. A preferred oral dosage form comprises tablets, capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract. The oral dosages contemplated
25 in accordance with the present invention will vary in accordance with the needs of the individual patient as determined by the prescribing physician.

In orally administering to a patient the compounds of this
30 invention for potentiating the differentiating activity of retinoids having $RAR\alpha$ activity which are used for treating acute promyelocytic leukemia, or head, neck or breast tumors, the compound of the invention is generally given to adults daily in an amount of about 1 to 10 times the amount of retinoid having $RAR\alpha$ activity. The amount
35 administered of the retinoid having $RAR\alpha$ activity is from about 20 mg/m^2 to about 300 mg/m^2 daily, preferably from about 50 mg/m^2 to about 100 mg/m^2 daily, with the precise dosage being varied depending upon the size and weight of the patient. In general, the



combination treatment is carried out for a period of about three months.

The compounds of the invention or their pharmaceutically acceptable salts or hydrolyzable esters and the retinoids having $RAR\alpha$ activity may be administered separately in accordance with the invention, but are preferably administered as an oral composition containing the compound of the invention, its pharmaceutically acceptable salts or esters, in combination with the retinoid having $RAR\alpha$ activity in an amount sufficient for the combination to treat acute promyelocytic leukemia or head, neck or breast tumors.

Generally the preferred unit oral dosage form is tablets or capsules containing from 10 to 50 mg of the retinoid having $RAR\alpha$ activity and a compound of the invention in an amount from 1 to 10 times the amount of the retinoid having $RAR\alpha$ activity, its pharmaceutically acceptable salts or its pharmaceutically acceptable hydrolyzable esters. Thus, the amount of the compound of the invention in each tablet or capsule can be from 10 to 500 mg. These tablets or capsules can be administered once or twice daily depending upon the weight and size of the patient.

In accordance with this invention, the topical and oral administration of the compounds of the invention, their pharmaceutically acceptable salts and their pharmaceutically acceptable hydrolyzable esters, are effective in treating all forms of acne such as inflammatory and non-inflammatory.

For topical administration to the skin, compositions containing a compound of the invention in a pharmaceutically acceptable carrier are preferably prepared as ointments, tinctures, creams, gels, solutions, lotions, sprays, suspensions, shampoos, hair soaps, and the like. In fact, any conventional composition utilized for application to the scalp or skin can be utilized in accordance with this invention. Among the preferred methods of applying the composition containing the active ingredient of the invention is to apply the active ingredient of the invention in the form of a gel, lotion or cream. The pharmaceutical preparation for topical administration to the skin can



be prepared by mixing the aforementioned active ingredient of the invention with non-toxic, therapeutically inert, solid or liquid carriers customarily used in such preparations. These preparations should contain at least about 0.05 percent by weight of the active ingredient
5 of the invention based upon the total weight of the composition. Since the active ingredient of the invention is relatively non-toxic and non-irritating, it may be used in topical compositions in amounts exceeding 3.0% percent. It is preferred that these preparations contain about 1 to 2% percent by weight of the active ingredient of the invention
10 based upon the total weight of the composition. It is also preferred to apply these preparations once or twice daily to the skin. These preparations can be applied according to the need of the patient. In carrying out this invention, the active ingredient of the invention can also be applied in an aqueous solution or an alcohol solution such as
15 ethyl alcohol.

In preparing the topical preparations described above additives such as preservatives, thickeners, perfumes and the like conventional in the art of pharmaceutical compounding of topical preparations can
20 be used. In addition, conventional antioxidants can be incorporated into the topical preparations containing the aforementioned active agent of the invention. Among the conventional antioxidants which can be utilized in these preparations are included N-methyl- α -tocopherolamine, tocopherols, butylated hydroxyanisole, butylated
25 hydroxytoluene, ethoxyquin and the like.

Conventional perfumes and lotions generally utilized in topical preparations for the hair can be utilized in accordance with this invention. Furthermore, if desired, conventional emulsifying agents
30 can be utilized in the topical preparations of this invention.

Ointment formulations containing the active ingredient of the invention may comprise admixtures of a semi-solid petroleum hydrocarbon with a solvent dispersion of the active ingredient of the
35 invention.

Cream compositions containing the active ingredient of the invention preferably comprise emulsions formed from a water phase



of a humectant, a viscosity stabilizer and water, an oil phase of a fatty acid alcohol, a semi-solid petroleum hydrocarbon and an emulsifying agent and a phase containing the active ingredient of the invention dispersed in an aqueous stabilizer-buffer solution. Stabilizers may be
5 added to the topical preparation. Any conventional stabilizer can be utilized in accordance with this invention. In the oil phase, fatty acid alcohol components function as a stabilizer. These fatty acid alcohol components are preferably derived from the reduction of a long-chain saturated fatty acid of at least about 14 carbon atoms. Cream-base
10 pharmaceutical formulations containing the active ingredient of the invention may be composed of, for example, aqueous emulsions containing a fatty acid alcohol, semi-solid petroleum hydrocarbon, 1,2-ethyleneglycol and an emulsifying agent.

15 Generally, treatment of acne, whether inflammatory or noninflammatory, may be affected by orally administering to a patient from 0.1-10 mg/kg of a compound of the invention once or twice daily. Treatment of acne may be affected by topically applying a topical composition containing a compound of the invention in a
20 amount from about 0.05% to about 3% by weight, preferably about 1% to about 2% by weight, once or twice daily.

The dosage for treatment typically depends on the route of administration, the age, weight, size and disease condition of the
25 individual.

Preferred compounds of the invention are:

- (2E,4E,6Z,8E)-3,6,7-trimethyl-9-(2,6,6-trimethyl-1-cyclohexen-
30 1-yl)-2,4,6,8-nonatetraenoic acid;
(2E,4E)-3-methyl-5-(2-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl) ethenyl)-1-cyclohexen-1-yl)-2,4-pentadienoic acid;
(all-E)-6-bromo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid;
35 (all-E)-6-iodo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid;
(all-E)-6-chloro-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid



(2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclopenten-1-yl)-2,4-pentadienoic acid;

(2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohepten-1-yl)-2,4-pentadienoic acid;

5 (2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cycloocten-1-yl)-2,4-pentadienoic acid;

(2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-phenyl)-2,4-pentadienoic acid;

10 (2E,4E)-3-methyl-5-(3-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-2-thienyl)-2,4-pentadienoic acid;

(2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoic acid;

(2E,4E)-3-methyl-5-(4-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoic acid;

15 (2E,4E)-3-methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid;

(2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclohept-1-enyl]-penta-2,4-dienoic acid; and

20 (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-phenyl]-penta-2,4-dienoic acid.

Methods for determining the binding and transactivation properties of retinoids with regard to the RAR receptors and RXR receptors are known in the art, e.g., Levin et al., *Nature*, **355**:359-361
25 (January 23, 1992); Allenby et al., *Proc. Natl. Acad. Sci. USA*, **90**:30-34 (January, 1993); Allenby et al., *J. Biol. Chem.*, **269**:16689-16695 (June 17, 1994). Methods essentially as described in those publications were used to determine the binding and transactivation properties of retinoids reported in the Examples herein.

30

The activity of the compounds of the invention for use in treating acne may be determined by any conventional means. For example, the ability of the compounds of the invention to inhibit the proliferation of sebocytes is a standard model of acne treatment. The
35 sebocyte antiproliferative activity of the compounds of the invention maybe determined in accordance with the procedure of Example 20(1).



Additionally, the ability of the compounds of the invention to reduce the size of Rhino mouse utricles is another standard model of acne treatment. This activity may be determined in accordance with the procedure of Example 20(2).

5

Further, the ability of the compounds of the invention to reduce the size of Syrian Golden Hamster sebaceous glands is another standard model of acne treatment. This activity may be determined in accordance with the procedure of Example 20(3).

10

The ability of the compounds of the invention to potentiate the RAR α activity of retinoids may be determined by any conventional means. Thus, the ability of the compounds of the invention to potentiate the RAR α activity of retinoids may be determined by measuring the activity of the combination of a compound of the invention with a retinoid having RAR α activity in a standard screening assay which has known relevance to a disease state for which the retinoid is known to be useful for treatment. The reduction of the concentration of the retinoid having RAR α activity needed to obtain a particular level of activity, or an increase in activity of the retinoid at a constant concentration, would demonstrate the potentiating activity of the compounds of the invention where the concentration of the compound of the invention is one at which the compound of the invention has little or no activity by itself.

25

For example, the results shown below of the ability of the compounds of the invention to potentiate the activity of retinoids in differentiating HL-60 cells (a standard model of human leukemia) demonstrate the potentiating activity of the compounds of the invention. The ability of the compounds of the invention to potentiate the activity of retinoids having RAR α activity in differentiating HL-60 cells may be carried out in accordance with Example 18.

30

Additionally, the results shown below of the ability of the compounds of the invention to potentiate the activity of retinoids having RAR α activity in inhibiting mouse B cell activation (a standard model of immunosuppression) demonstrates the potentiating activity of the compounds of the invention. The ability of the compounds of

35

the invention to potentiate the activity of retinoids in inhibiting mouse B cell activation may be carried out in accordance with Example 19.

5 Further, the results shown below of the ability of the compounds of the invention to potentiate the activity of retinoids having $RAR\alpha$ activity in inhibiting the growth of a breast carcinoma cell line (a model of a solid tumor) demonstrates the potentiating activity of the compounds of the invention. The ability of the compounds of the
10 invention to potentiate the activity of retinoids in inhibiting the growth of a breast carcinoma cell line may be carried out in accordance with Example 21.


The compounds of the invention may be prepared by any
15 conventional means. The preferred methods are illustrated in the following schemes:

This Sheet Has Been Replaced







SCHEME 1a
(R_{10} and R_{20} = lower-alkyl)




SCHEME 1b
(R_{11} = lower-alkyl; R_{21} = halogen)



SCHEME 1c
(R_{12} = lower-alkyl or halogen; R_{22} = lower-alkyl, F or Cl)




SCHEME 1d
(R_{13} = lower-alkyl or halogen; R_{23} = Br)






SCHEME 2




SCHEME 3





This Sheet Has Been Replaced




SCHEME 4








SCHEME 6




This Sheet Has Been Replaced

SCHEME 7






SCHEME 8





SCHEME 9



- 5 Schemes 1a-1d show the preferred methods for preparing intermediate esters for use in obtaining the compounds of formula I in which R₁ and R₂ are *not* taken together to form a ring. Scheme 1a is a route to compounds of formula I in which R₁ and R₂ are independently lower-alkyl. Scheme 1b is a route to compounds of
- 10 formula I in which R₁ is lower-alkyl and R₂ is halogen or lower-alkyl. Scheme 1c is a route to compounds of formula I in which R₁ is lower-alkyl or halogen and R₂ is lower-alkyl, fluorine or chlorine. Scheme 1d is another route to compounds of formula I in which R₁ is lower-alkyl or halogen and R₂ is bromine. However, when R₁ is alkyl, the
- 15 compounds of formula I where R₂ is bromine are preferably prepared via the route of Scheme 1b.



In Scheme 1a, exposure of 1 to strong base (e.g., lithium diisopropylamide) and alkylation of the enolate with an alkyl halide results in the formation of ester 3 which after exposure to base under
5 equilibrating conditions (e.g., sodium ethoxide in refluxing ethanol) yields the ester 3 as predominantly one isomer (Z).

Scheme 1b is preferably used to obtain compounds of formula I where R^2 is halogen. However, Scheme 1b may also be used for the
10 preparation of compounds of formula I in which R_2 is lower-alkyl. The addition of the cuprate $(R_1)_2LiCu$ to the acetylene 7 (*Carotenoids*, Otto Isled, ed. (Birkhauser Verlage, Basel, 1971)) yields the new cuprate from syn addition which on quenching with a suitable halide (e.g., iodine in dioxane) yields 3'; $R_2=I$. Quenching the cuprate with an
15 alkyl halide will result in the ester 3' where R_2 is alkyl. The advantage of the cuprate chemistry is in the formation of a single isomer in most cases.

Scheme 1c is preferably used to obtain compounds of formula I
20 where R^2 is lower-alkyl. Commercially available starting materials; e.g., β -ionone 14 ($R_{12}=CH_3$) are coupled with a suitable phosphonate 15 (*Carotenoids, supra*) to obtain the desired ester 3''.

Scheme 1d may be used to form compounds of formula I where
25 R_2 is bromine (G. Kobrich et al., *Liebigs Ann. Chem.*, 51:704 (1967)). The ketone 14 is converted to the alkene 16 by the referenced method. The known mixture of bromo acids 16 is converted to the mixture of esters 3''' (e.g., $R_1=Me$; $R_2=Br$) which are then separated by HPLC and then transformed into the final products as before.

30

With the esters 3, 3', 3'', or 3''' in hand the final products are prepared through standard procedures (*Carotenoids, supra*). For example, the reaction may be carried out as shown in Scheme 2. In Scheme 2, reduction of any of the esters 3, 3', 3'', or 3''' to the
35 alcohol followed by reoxidation with manganese dioxide leads to the aldehyde 4. The aldehyde 4 is then coupled with the phosphonate 5 to yield the final product as the methyl ester 6. Base hydrolysis of 6 produces the free acid.



The compounds of formula I in which R₁ and R₂ taken together are C₃₋₁₃-alkylene are readily prepared as shown in Scheme 3 (R.M. Coates et al. *J.Org.Chem.*, **47**:3597 (1982)). Thus, the cyclic ketone 8 (e.g., cyclopentanone or cyclohexanone, etc.) is exposed to phosphorus tribromide in dimethylformamide to give the bromoaldehyde 9 (Coates et al., *supra*) which is then coupled with the phosphonium salt 10¹ to give the vinyl bromide 11. This vinyl bromide is then converted to the aldehyde 12 via transmetalation and reaction with dimethylformamide. With the new aldehyde in hand, the final product 13 is readily formed by coupling 12 with phosphonate 5. Hydrolysis then furnishes the desired acid.

Scheme 7 shows the preferred method for the preparation of intermediate 12 for use in Scheme 3, wherein R¹ and R² taken together are C₃₋₁₃-alkylene. Thus the ketone 8 is converted to the ester 36 by known methods (e.g., *Org. Synthesis*, Coll Vol. 5:198 (1973)) and then transformed into the enolphosphate 37. Displacement of the phosphate group with dimethyl cuprate (*J. Org. Chem.*, **53**: 2984 (1988)) then gives the ester 38. Exposure of 38 to lithium diisopropylamide followed by the addition of cyclocitral 39 gives the lactone 40 (*Tet. Letters*, **21**:2509 (1980)). Treatment of the lactone 40 with potassium t-butoxide and subsequently quenching the reaction product with methyl iodide yields the ester 41. Reduction with diisobutylaluminium hydride followed by subsequent oxidation with manganese dioxide then yields the aldehyde 12.

The routes shown in Schemes 4, 5 and 6 may be employed to obtain the compounds of formula I in which R₁ and R₂ taken together with the carbon atoms to which they are attached are 5-6 membered aromatic rings (e.g., thiophene, benzene, pyridine, etc.) . Thus, in Scheme 4, a route to the benzene-containing structure 22 is shown. Phthalide is treated with triphenylphosphine hydrobromide and the resulting salt 17 is then coupled with the aldehyde 18 to give the acid ester 19 as shown. Reduction of the acid ester 19 via the acid chloride (not shown) yields the benzyl alcohol 20 which is then converted to the aldehyde 21, and then coupled with the



cyclogeranylphosphonium ylide **10** to give the ester **22** which yields the acid after hydrolysis.

The various thiophene derivatives are prepared from a suitable
5 bromothiophene as shown in Schemes 5 and 6. For example, in
Scheme 5, 2,3-dibromothiophene **23** is selectively metalated and
exposed to dimethylformamide to give the aldehyde **24** which is then
homologated to the ester **25** with triethylphosphonoacetate.
Reduction of the ester group gives the alcohol **26** which is protected
10 as the acetal **27** which now allows one to again metalate and quench
with dimethylformamide to yield the aldehyde **28**. Condensation of
28 with the cyclogeranylphosphonium ylide followed by acid
treatment gives the alcohol **29**. The alcohol **29** is then oxidised to the
aldehyde **30** with manganese dioxide, exposed to methyl lithium and
15 again oxidised with manganese dioxide to furnish the methyl ketone
31. Chain extension with triethyl phosphonoacetate then gives the
desired material as the ester **32** which yields the acid on hydrolysis.
Other analogs can be prepared in a similar fashion (see examples).


20 In Scheme 6, aldehyde **24** is coupled with the cyclogeranyl-
phosphonium ylide **10** to give **33** which is selectively metalated and
exposed to dimethylformamide to give the aldehyde **34**. Chain
extension with triethyl phosphonoacetate then gives the desired
material as the ester **35**, which yields the acid on hydrolysis.

25

Schemes 8 and 9 show the preferred methods for preparing
compounds of formula I wherein the C₇-C₈ bond is a triple bond.

In Scheme 8, the aldehyde **42** is coupled in a Wittig-Horner
30 reaction with 4-(diethoxy-phosphonyl)-3-methyl-but-2-enoic acid
ethyl ester in the presence of a base, e.g. NaH, to give the ester **43**.

2,2,6-Trimethylcyclohexanone is reacted with trimethylsilyl-
acetylene (TMS-acetylene) using a strong base, e.g. butyl lithium.
Elimination of water with Burgess-reagent (methoxycarbonylsulfa-
35 moyl-triethylammonium hydroxide, inner salt) and removal of the
silyl protecting group with tetrabutylammonium fluoride leads to 2-
ethynyl-1,3,3-trimethyl-1-cyclohexene.



This cyclohexene derivative is coupled with the ester **43** using the Pd (Ph₃P)₄/CuI complex as catalyst and piperidine as solvent. The resulting ester is then hydrolysed to the acid **III**.

In Scheme 9, 2-ethynyl-benzyl alcohol (compound **44**, wherein R is H) is reacted with trimethylsilyl chloride. The protected alcohol (**44**, R = SiMe₃) is reacted with 2,2,6-trimethyl-cyclohexanone after deprotonation with butyl lithium, to form the adduct **45** wherein R' is SiMe₃. Removal of the silyl protecting group with a base, e.g. aqueous potassium hydroxide, followed by acetylation with acetyl chloride and triethylamine leads to the acetate **45** (R' = acetyl).

Water is eliminated from the cyclohexanol derivative **45** by treatment with Burgess reagent to give the corresponding cyclohexene derivative. This is followed by hydrolysis of the acetyl group and oxidation with MnO₂ of the primary alcohol to give the aldehyde **46**. The aldehyde **46** is reacted with 4-(diethoxy-phosphonyl)-3-methyl-but-2-enoic acid ethyl ester in a Wittig-Horner reaction to give the acid **III** after hydrolysis of its corresponding ester.

The following examples illustrate the invention. In the examples, concentration involves evaporation of the solvent employing a rotary evaporator at 40°C and 20mm Hg vacuum. HPLC refers to high performance liquid chromatography employing a Waters Prep 500 with silica cartridges. All intermediates and final products were characterized by HNMR spectroscopy.

Example 1

Preparation of (2E,4E,6Z,8E)-3,6,7-Trimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid

(All-E)-Ethyl-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoate (**1**; R₁=Me; 13.1 g) was dissolved in tetrahydrofuran (25 ml) and then added to a freshly prepared solution of lithium diisopropylamide (1.2 equivalents with respect to the starting ester from diisopropyl amine and n-butyllithium; 1.6M in hexanes) dissolved in tetrahydrofuran (100 ml) at -70°C. The resulting solution was stirred a further 1 hr. at this temperature and then treated with methyl iodide (10 ml) and allowed to warm to room



- temperature. Saturated aqueous ammonium chloride was added and the organic materials were isolated by extraction with a hexane/ethylacetate mixture (4:1). Removal of the solvents *in vacuo* gave the alkylated product (14 g) as an oil. This material was
- 5 dissolved in methanol (100 ml) containing sodium methoxide (10 ml; 4.6M in methanol) and heated at reflux for 2 hours. After this time the mixture was cooled to room temperature, treated with water and extracted with hexane/ethylacetate as above. Removal of the solvents *in vacuo* gave crude methyl-(2Z,4E)-2,3-dimethyl-5-(2,6,6-trimethyl-
- 10 1-cyclohexen-1-yl)-2,4-pentadienoate (13.2 g) as a 9:1 mixture of isomers about the 2,3 double bond. This material was dissolved in hexane (150 ml) cooled to -70°C and then treated with an excess of diisobutylaluminum hydride (1M in hexane) and warmed to 0°C. Diethyl ether (200 ml) was then added followed by an aqueous
- 15 solution of Rochelle salt (20%; 20 ml). The mixture was then carefully warmed to room temperature when a slight exothermic reaction set in. The mixture was allowed to heat to 35°C and then cooled to room temperature. Solid magnesium sulphate (50 g) was then added and the solids were filtered off.
- 20 Removal of the solvents *in vacuo* gave the crude alcohol as an oil. This material was dissolved in hexane (20 ml) and added to a slurry of manganese dioxide (102 g) in a mixture of hexane-ether (1:1; 400 ml) cooled to 5°C and stirred for 1.5 hours at this temperature and then for a further 1 hour at room temperature. The solids were
- 25 then filtered off and the solution was concentrated *in vacuo*. Chromatography of the residue by HPLC (5% ether-hexane solvent system) gave pure (2Z,4E)-2,3-dimethyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienal (6 g; 51% overall yield from the ethyl ester).
- 30 Sodium hydride (1.3 g; 64% in oil) was washed with hexane, dried *in vacuo* and then suspended in tetrahydrofuran (60 ml) at 5°C. A solution of methyl 3-methyl-4-diethylphosphonocrotonate in tetrahydrofuran (8.6 g in 30 ml) was then added to the above suspension to yield a clear solution of the sodium salt (note: if turbid,
- 35 the mixture is filtered through CELITE diatomaceous earth). The clear solution was then cooled to 10°C and treated with the above aldehyde (6 g) dissolved in tetrahydrofuran (20 ml) and then stirred at room




temperature for 30 minutes. Hexane was then added and the mixture was washed with water, dried (magnesium sulphate), filtered free of solids and concentrated. Crystallization of the residue from hexane yielded pure methyl (2E,4E,6Z,8E)-3,6,7-Trimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate as a yellow crystalline solid. This material was dissolved in a mixture of ethanol-water (100 ml; 9:1) containing potassium hydroxide (4 g) and heated at reflux for 20 minutes. The mixture was then cooled to room temperature, poured into cold aqueous phosphoric acid (2M) and the solids were extracted into dichloromethane. Removal of the solvents *in vacuo* and crystallization of the residue from acetonitrile gave (2E,4E,6Z,8E)-3,6,7-Trimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid (3.8 g) as a pale yellow colored crystalline solid. This material showed the characteristic peaks in the proton magnetic resonance spectrum for the E,E,Z,E polyene system.

Example 2

Preparation of (All-E)-6-Bromo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid

A mixture of (2E,4E) and (2Z,4E)-2-bromo-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoic acid (75 g) was dissolved in dimethylformamide (500 ml) and slowly added to a suspension of sodium hydride (10.5 g; 65% in oil) in tetrahydrofuran (1100 ml) at 10°C and then stirred until all hydrogen evolution ceased. Methyl iodide (50 g) was then added and the resulting mixture was heated for 2 hours at 50-60°C, poured onto an ice-water mixture and extracted with hexane. The hexane extracts were washed with water, dried (magnesium sulphate) and concentrated. The mixture of methyl esters was then separated by HPLC (2.5% ether/hexane) to give pure methyl (2Z,4E)-2-bromo-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoate (20 g) and methyl (2E,4E)-2-bromo-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoate (37 g).

The (2E,4E)-2-bromo-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoate (37 g) was reduced to the alcohol as in Example 1 and then immediately exposed to manganese dioxide to give the unstable aldehyde (15 g). This material was then



converted to ethyl (All-E)-6-bromo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate and subsequently hydrolyzed to (All-E)-6-Bromo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, as in Example 1.

5

Example 3

Preparation of (All-E)-6-Iodo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid

A slurry of cuprous bromide dimethylsulfide complex (10.3 g) in tetrahydrofuran (500 ml) at 0°C was treated with a solution of methyl
10 lithium in ether (1.4M; low bromide), stirred a further 15 minutes and then cooled to -70°C. To this cold clear solution was added ethyl (E)-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-4-penten-2-ynoate (10 g) dissolved in tetrahydrofuran (50 ml) and the mixture was stirred for 2 hours and then treated with a solution of iodine in tetrahydrofuran
15 (13 g in 100 ml) over 0.5 hours. After this period, the mixture was warmed to -60°C and poured into aqueous ammonium chloride solution, and the organic materials were extracted into hexane. The hexane extracts were washed with dilute aqueous sodium thiosulphate solution, dried (sodium sulphate), and concentrated at
20 room temperature to yield the unstable iodoester which was purified by HPLC (2.5% ether/hexane) giving pure ethyl (2E,4E)-2-iodo-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoate (5 g). This ester was transformed into the corresponding aldehyde and was then coupled with the phosphonate as in previous examples, and
25 the resulting retinoic acid ester analog was hydrolyzed to yield the pure (All-E)-6-iodo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid as a pale yellow solid after crystallization from a hexane/tetrahydrofuran mixture.

Example 4

30 Preparation of (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohexen-1-yl)-2,4-pentadienoic acid

A suspension of ((2,6,6-trimethyl-1-cyclohexen-1-yl)methyl)-triphenylphosphonium chloride (18 g) in tetrahydrofuran (300 ml) was cooled to -60°C, treated dropwise with n-butyllithium (1.4M in



hexane; 32 ml), and then stirred a further 10 minutes. To this cold solution was added the 2-bromocyclohexene-1-carboxaldehyde (8.5 g, 75% pure by HNMR analysis) dissolved in tetrahydrofuran, and the mixture was allowed to warm to room temperature after which it was stirred for a further 2 hours. Hexane was then added to the reaction and the resulting mixture was washed with water, 50% aqueous methanol and dried (magnesium sulphate). Removal of the solvents yielded the crude (E)-1-bromo-2-(2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-cyclohexene (12.5 g) as a mixture of isomers which was used, as is, in the next step. Standard transmetalation and reaction with DMF yielded a crude aldehyde (4.5 g) which was dissolved in tetrahydrofuran (100 ml) and reacted with an excess of the phosphonate as in Example 1 to give methyl (2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohexen-1-yl)-2,4-pentadienoate (3 g) as an oil after purification by HPLC (2.5% ether in hexane). Hydrolysis with aqueous potassium hydroxide solution gave crystalline (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohexen-1-yl)-2,4-pentadienoic acid (1.6 g from hexane-tetrahydrofuran).

20

Example 5

Preparation of (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclopenten-1-yl)-2,4-pentadienoic acid.

As in Example 4, 2-bromocyclopentene-1-carboxaldehyde was converted to (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclopenten-1-yl)-2,4-pentadienoic acid ethyl ester which on hydrolysis with base gave (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclopenten-1-yl)-2,4-pentadienoic acid.

30

Example 6

Preparation of (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohepten-1-yl)-2,4-pentadienoic acid

As in Examples 4 and 5, 1-bromocycloheptene-2-carboxaldehyde was converted to (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-



trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohepten-1-yl)-2,4-pentadienoic acid ethyl ester which gave (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohepten-1-yl)-2,4-pentadienoic acid after hydrolysis with base.

5

Example 7


Preparation of (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cycloocten-1-yl)-2,4-pentadienoic acid

As in the above Examples, 1-bromocyclooctene-2-carboxaldehyde was converted into (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cycloocten-1-yl)-2,4-pentadienoic acid ethyl ester and subsequently into (2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cycloocten-1-yl)-2,4-pentadienoic acid by base hydrolysis.

Example 8

15 Preparation of (2E,4E)-3-methyl-5-(2-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl) ethenyl)-1-phenyl)-2,4-pentadienoic acid

As shown in Scheme 4, phthalide (0.1 Mol) and triphenylphosphine hydrobromide (0.1 Mol) were heated at 200°C for two hours, cooled to room temperature and then digested with hot acetonitrile to yield the salt 17 (39 g) as a white solid. A solution of this salt (4.6 g) in dimethylsulphoxide (DMSO; 50 ml) at 5°C was treated with a solution of the sodium salt of DMSO (1M; 20 ml) followed by the aldehyde 18 (1.5 g) to yield a pale yellow colored reaction mixture. Water was then added and the resulting mixture was acidified with aqueous phosphoric acid (2M) and the acid 19 was isolated by extraction into ethyl acetate. The crude product (4.3 g) was dissolved in benzene and exposed to oxalyl chloride (3 ml) and dimethylformamide (3 drops), and then held at room temperature for 30 minutes. Removal of the solvents *in vacuo* followed by dissolution of the crude acid chloride in tetrahydrofuran (100 ml) yielded the alcohol 20 after the addition of sodium borohydride at -20°C and warming to room temperature. Purification of the crude alcohol by HPLC followed by crystallization from a hexane/ethylacetate mixture gave 3-methyl-5-(2-hydroxymethylphenyl)-2,4-pentadienoic acid



ethyl ester **20** as a colorless solid (1.1 g). Exposure of the alcohol **20** (1.1 g) to a slurry of manganese dioxide (11 g) in hexane/dichloromethane (5:1; 60 ml) at 0°C followed by stirring for a further 2 hours at room temperature gave the aldehyde **21** (1.1 g). A solution of the
5 phosphonium ylide derived from cyclogeranylphosphonium bromide **10** (1.3 g) in tetrahydrofuran (20 ml) and n-butyllithium at 10°C was then treated with the crude aldehyde **21** (1.0 g) and warmed to room temperature over 15-30 minutes. Dilution with water and extraction of the organic materials in to a hexane/ethylacetate mixture (4:1)
10 gave the crude adduct **22** as an oil. This material in hexane was passed through a plug of silicagel to yield the ester (0.8 g) as an oil. Hydrolysis of this material with aqueous potassium hydroxide in refluxing ethanol yielded the acid after acidification with mineral acid (2M phosphoric acid). Crystallization from a hexane/ethylacetate
15 mixture gave the pure (2E,4E)-3-methyl-5-(2-(2-((E)-2-(2,6,6-trimethyl-1-cyclohex-1-yl) ethenyl)-1-phenyl)-2,4-pentadienoic acid as a white solid.

Example 9.

Preparation of (2E,4E)-3-Methyl-5-(3-((E)-2-(2,6,6-trimethyl-1-
20 cyclohexen-1-yl) ethenyl)-2-thienyl)-2,4-pentadienoic acid

A solution of 2,3-dibromothiophene (0.1 mol) in diethyl ether (approximately 5% concentration) was treated with n-butyllithium (1.6M in hexane; 1.1equivalents) at -70°C and stirred for 30 minutes. Excess dimethylformamide was then added and the mixture was
25 warmed to room temperature, quenched with water, and then acidified with dilute aqueous phosphoric acid. Extraction with hexane gave the crude aldehyde which was then purified by HPLC. The total aldehyde from this run was then added to an excess of the sodium salt of triethylphosphonoacetate in tetrahydrofuran and the mixture was
30 stirred at room temperature for 1 hour and then quenched with water and acetic acid. The crude ester **25** was then added to an excess of diisobutylaluminum hydride in hexane at -40°C and the mixture was then warmed to 0°C and quenched with an aqueous solution of Rochelle salt (20%; 10 ml) and warmed to 32°C. Extraction with
35 hexane then gave the alcohol **26** which was converted to the acetal **27** with 2-methoxypropene. After purification of the acetal by HPLC, the



total product was dissolved in tetrahydrofuran ($\approx 5\%$ concentration) cooled to -70°C and then treated with n-butyllithium as before. After stirring a further 30 minutes at this temperature, an excess of dimethylformamide was added and the mixture was warmed to room temperature and quenched with aqueous ammonium chloride solution (20%) to give the aldehyde **28** after isolation with hexane and purification by HPLC. This aldehyde was then exposed to an excess (1.2 equiv.) of the ylide formed from cyclogeranylphosphonium bromide **10** and n-butyllithium in tetrahydrofuran and hexane at -70°C and then stirred a further 2 hours at room temperature. Addition of water and dilute aqueous phosphoric acid then yielded the alcohol **29** after extraction into hexane. This material was dissolved in diethyl ether (min. volume) and then added to a slurry of manganese dioxide (10 fold) in more ether (300 ml) at 0°C and the warmed to room temperature. After stirring for a further 1 hour, the solids were filtered off and removal of the solvent gave the aldehyde **30** after purification by HPLC. This material was then dissolved in ether, cooled to -10°C and exposed to an excess of methyl lithium in ether (1.4 equiv.) and subsequently warmed to room temperature. Addition of water and concentration of the organic phase gave the crude alcohol which was oxidised with manganese dioxide, as above, yielding the ketone **31**. Exposure of this material to an excess of the sodium salt of triethylphosphonoacetate in tetrahydrofuran at room temperature gave the desired ester **32** (R=ethyl) as a mixture of isomers about the newly formed double bond ($\approx 4:1$) with the desired isomer predominating. Purification of this mixture by HPLC and crystallization of the major isomer from hexane gave the pure ethyl-(2E,4E)-3-Methyl-5-(3-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-2-thienyl)-2,4-pentadienoate. Hydrolysis with aqueous potassium hydroxide solution in refluxing ethanol as in Example 8 gave the pure (2E,4E)-3-Methyl-5-(3-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-2-thienyl)-2,4-pentadienoic acid after crystallization from a tetrahydrofuran/hexane mixture.



Example 10.

Preparation of (2E,4E)-3-Methyl-5-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl) ethenyl)-3-thienyl)-2,4-pentadienoic acid

As in Example 9, 2,3-dibromothiophene was converted into the aldehyde **24** and then exposed to the ylide derived from cyclogeranylal phosphonium bromide **10** and n-butyllithium to give the adduct **33**. Treatment of the bromo compound **33** with n-butyllithium in hexane/tetrahydrofuran as in Example 9, followed by a excess of dimethylformamide, gave aldehyde **34** after workup with aqueous phosphoric acid. This material was then coupled with the phosphonate **5** as in Example 1 to give the methyl-(2E,4E)-3-methyl-5-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoate **35** (R=methyl) as a mixture of isomers about the terminal double bond. Purification by HPLC gave methyl-(2E,4E)-3-methyl-5-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoate which after hydrolysis as above gave the pure (2E,4E) -3-methyl-5-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl) ethenyl)-3-thienyl)-2,4-pentadienoic acid on crystallization from a tetrahydrofuran/hexane mixture.

Example 11

Preparation of (2E,4E)-3-methyl-5-(4-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoic acid

Treatment of 3,4-dibromothiophene as in Example 10 gives (2E,4E)-3-Methyl-5-(4-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoic acid.

Example 12

Preparation of (All-E)-6-chloro-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid.


A solution of triethyl 2-chlorophosphono acetate (*J. Org. Chem.*, 51:5467 (1986)) (0.12M) in tetrahydrofuran was treated with sodium hydride (64% oil suspension; 0.12M) and stirred at room temperature to give a clear solution of the anion. To this mixture was added β -

ionone (0.1M) and the reaction was heated at 45°C overnight. Water was then added and the products were extracted into hexane/ethyl-acetate (4:1). Removal of the solvents yielded the coupled product as a mixture (1:1) of double bond isomers from which the desired
5 isomer, ethyl-(2E,4E)-2-chloro-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoate, was separated by HPLC. Reduction of this ester with diisobutylaluminum hydride as in Example 1, followed by oxidation with manganese dioxide as before, gave
(2E,4E)-2-chloro-3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-
10 2,4-pentadienal. This material was then coupled with methyl 3-methyl-4-diethylphosphonocrotonate as in Example 1 to give methyl (all-E)-6-chloro-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate. Hydrolysis of the ester as before, and
crystallization of the acid from a mixture of tetrahydrofuran and
15 hexane, yielded pure (all-E)-6-chloro-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-yl)-2,4,6,8-nonatetraenoic acid as a yellow colored solid.

Example 13

20 Preparation of All-E-3,7-Dimethyl-9-[(2-methoxy-4-methyl-6-octyloxy)phenyl]-2,4,6,8-nonatetraenoic acid.

A solution of 2,6-dihydroxy-4-methyl-benzoic acid in acetone (50.4 g; 750 ml) was treated with methyl iodide (100 ml) and potassium carbonate (124.2 g) and heated at reflux for 18 hours. The
25 mixture was then cooled to room temperature and filtered free of solids. Concentration of the solution gave the crude product which was dissolved in ethylacetate and washed with aqueous sodium hydroxide solution (1N; cold). Removal of the solvents *in vacuo* then gave methyl 2,6-dimethoxy-4-methyl -benzoate (54 g). This material
30 (52.5 g) was dissolved in dichloromethane (1000 ml) cooled to -70° and treated with a solution of borontrichloride in the same solvent (29.3 g/100 ml; 180 ml). This mixture was then warmed up to room temperature and stirred for a further 45 minutes and then poured onto ice. The organic layer was separated, washed with more water,
35 dried (magnesium sulphate), filtered and concentrated.



The residue was then purified by high performance preparative liquid chromatography (HPLC) using a Waters prep.500 chromatograph (7% ethyl acetate/hexane eluent) to give pure methyl 2-hydroxy-6-methoxy-4-methyl benzoate as a solid (28.3 g). A
5 solution of this material (35 g) in methyl ethyl ketone (700 ml) containing potassium carbonate (27.1 g) was treated with 1-octyliodide (34.2 g) and heated at reflux for 20 hours. The reaction mixture was cooled filtered free of solids and the filtrate was concentrated and then redissolved in a mixture of hexane and ethyl
10 acetate. This solution was then washed with aqueous base (1N sodium hydroxide), water, dried (magnesium sulphate) and concentrated to dryness. Purification by HPLC as before gave pure methyl 2-methoxy-6-octyloxy-4-methyl-benzoate (51.8 g).

A solution of this material (51.8 g) in toluene (500 ml) was
15 cooled to -60° and treated with a solution of diisobutylaluminum hydride (25% in hexane; 281 ml) and then warmed to room temperature. The reaction mixture was then carefully treated with aqueous methanol (100 ml; 1:1) with cooling so that the temperature was kept at 20° followed by the addition of hexane (500 ml) and
20 magnesium sulphate. The solids were then filtered off and the solvents were removed *in vacuo* to yield the crude alcohol. This material (47 g) was dissolved in acetonitrile (500 ml) containing triphenylphosphonium hydrobromide (54.9 g) and heated at reflux for 22 hours. The solvents were then removed *in vacuo* and the crude
25 salt was dried at room temperature at 0.1 mm pressure (this material can be crystallised from tetrahydrofuran to give pure [(2-methoxy-6-Octyloxy-4-methyl)phenyl]methyl-triphenylphosphonium bromide). This salt was then converted into All-E-3,7-Dimethyl-9-[(2-methoxy-4-methyl-6-octyloxy)phenyl]-2,4,6,8-nonatetraenoic acid as
30 described in U.S. Patent No. 4,894,480, Example 5.

Example 14

Preparation of (E)-2-(2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-cycloheptene carboxaldehyde

5

As shown in Scheme 7, cycloheptanone (152 g) was converted to the ester (Org.Syn. Coll., 5: 198 (1973); 232 g), transformed into the enolphosphate 37 (274 g) and subsequently treated with lithium dimethylcuprate to yield ethyl-2-methyl-cyclohept-1-eneoate 38
10 (119 g). A solution of ethyl-2-methyl-cyclohept-1-eneoate (91 g) in tetrahydrofuran was then added to a solution of lithium diisopropylamide (0.53 Mol) and then quenched with cyclocitral 39 (76 g) to yield the lactone 40 (113 g) after acid work up. Exposure of
15 40 to potassium tertiarybutoxide in tetrahydrofuran followed by an excess of methyl iodide gave the methyl ester 41 (111 g). Reduction of the above ester with diisobutylaluminium hydride followed by oxidation with manganese dioxide as in Example 1 furnished the aldehyde 12 (n=3)(98 g).

20

Example 15

A: Preparation of (2E, 4E)-3-Methyl-5-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid ethyl ester.

25

(2E,4E)-5-(2-Bromo-cyclopent-1-enyl)3-methyl-penta-2,4-dienoic acid ethyl ester (1.43 g) was dissolved in 5 ml of benzene. At ambient temperature was added successively: 293 mg of Pd(Ph₃P)₄, 95 mg of CuI, 147 mg of (Ph)₃P, and 8 ml of piperidine. To this mixture was added via dropping funnel within 1 hour 2-ethynyl-
30 1,3,3-trimethyl-1-cyclohexene (745 mg) dissolved in 5 ml of benzene. After 4.5 hours, additional acetylene (350 mg) was added and stirring continued for 30 minutes. The mixture was then poured into crushed ice/HCl, extracted with EtOEt, washed twice with water, dried over Na₂SO₄, and evaporated to dryness. Medium pressure
35 chromatography (SiO₂, hexane/AcOEt = 98/2) yielded 1.478 g of (2E, 4E)-3-Methyl-5-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid ethyl ester as a yellow oil.



The prerequisite (2E,4E)-5-(2-bromo-cyclopent-1-enyl)-3-methyl-penta-2,4-dienoic acid ethyl ester was synthesized as follows:

2.03 g of NaH (50% in mineral oil) was suspended in 120 ml of
5 DMF. 4-(Diethoxy-phosphinyl-3-methyl-but-2-enoic acid ethyl ester
(12.9 g) was added at 0°C. The mixture was stirred for 15 minutes at
0°C and for 30 minutes at RT. After recooling to 0°C, 2-bromo-
cyclopent-1-ene-carbaldehyde (5.72 g), dissolved in 11 ml of DMF,
was added drop by drop and allowed to react for 10 minutes at 0°C
10 and for 2 hours at RT. The mixture was then poured into crashed ice,
extracted with EtOEt, washed with sat. NaCl-solution, dried over
Na₂SO₄, and evaporated to dryness. Purification of the residue by
flash chromatography (silica gel, hexane/AcOEt = 97/3) and
crystallization from hexane/trace amounts of AcOEt yielded finally
15 3.408 g of pure (2E,4E)-5-(2-bromo-cyclopent-1-enyl)-3-methyl-
penta-2,4-dienoic acid ethyl ester as yellowish crystals of mp. 85-
86°C.

The prerequisite 2-ethynyl-1,3,3-trimethyl-1-cyclohexene was
20 synthesized according to standard procedures by addition of the Li-
derivative of TMS-acetylene to 2,2,6-trimethylcyclohexanone,
dehydration by treatment with Burgess-reagent (methoxy-
carbonylsulfamoyl-triethylammonium hydroxide, inner salt), and
finally desilylation with tetrabutylammonium fluoride. It has to be
25 used immediately due to its instability.

B: Preparation of (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-
enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid.

30 (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-
enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid ethyl ester (1.
47 g) was dissolved in 14 ml of THF/EtOH = 1/1. 3N aqueous NaOH
(7.0 ml) was added and the reaction flask kept in the dark. After
stirring for 16 hours at ambient temperature, the mixture was poured
35 onto crushed ice/HCl, extracted twice with EtOEt, washed with water,
dried over Na₂SO₄, and evaporated to dryness. Crystallization from
EtOEt/pentane afforded 1.31 g of (2E,4E)-3-Methyl-5-[2-(2,6,6-



trimethyl-cyclohex-1-enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid as yellow crystals of mp. 173-174°C.

Example 16

5

In analogy to Example 15 was prepared:

(2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclohept-1-enyl]-penta-2,4-dienoic acid as yellow crystals of mp.
10 166-167°C.

Example 17

Preparation of (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-phenyl]-penta-2,4-dienoic acid
15

229 mg of (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-phenyl]-penta-2,4-dienoic acid ethyl ester were dissolved in 8 ml of ethanol. After adding a solution of 411 mg of
20 potassium hydroxide in 2.5 ml of water, the reaction mixture was stirred at 50°C for 2 hours. The mixture was then poured onto ice/water, acidified with 2N hydrogen chloride and extracted with ethyl acetate. The organic phase was washed with water, dried over sodium sulfate and evaporated to give slightly yellow crystals which were
25 recrystallized from ethyl acetate/hexane. Yield 93 mg of (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-phenyl]-penta-2,4-dienoic acid, m.p. 194-196°C.

The starting material used in this example was prepared as follows:
30

970 mg of 2-ethynyl-benzyl alcohol were dissolved in 50 ml of diethyl ester. 1.9 ml of triethylamine was added, followed by dropwise addition of 0.9 ml of trimethylsilyl chloride. The reaction mixture was stirred at room temperature for 4 hours, poured onto
35 ice/5% aqueous sodium bicarbonate and extracted with ether. The oily residue obtained after drying and evaporation of the solvent was distilled to give 1.3 g of 2-ethynylbenzyl trimethylsilyl ether as a colourless oil, b.p. 85-89°C/0.8 mm.



This colourless oil was dissolved in 5 ml of tetrahydrofuran. After the dropwise addition of 3.9 ml of butyl lithium (1.6 molar in hexane) at -78°C , the reaction mixture was stirred at this
5 temperature for 30 minutes. A solution of 0.59 g of 2,2,6-trimethyl-cyclohexanone in 4 ml of tetrahydrofuran was dropped in and the reaction mixture was stirred at room temperature for 5 hours, resulting in a yellow solution. The yellow solution was poured onto ice water/10% aqueous ammonium chloride, extracted with hexane,
10 dried over sodium sulfate and evaporated. The yellow, oily residue was purified by flash chromatography (SiO_2 , hexane/5 % ethyl acetate) to give 1.7 g of a yellow oil.

The yellow oil was dissolved in 90 ml of tetrahydrofuran and
15 stirred for 6 hours at room temperature with 28.8 ml of a 0.5 normal aqueous solution of potassium hydroxide. The reaction mixture was poured onto ice/water, extracted with ether, washed with water, dried and evaporated. Purification of the residue by flash chromatography (SiO_2 , hexane/ethyl acetate = 7:3) and crystallization from ethyl
20 acetate/hexane yielded 1.1 g of white crystals, m.p. $120-121^{\circ}\text{C}$.

The white crystals were dissolved in 10 ml of tetrahydrofuran and sequentially treated with 679 mg of triethylamine and 400 mg of acetylchloride. After 4 hours of stirring at room temperature, the
25 reaction mixture was poured onto ice/1N hydrogen chloride, extracted with ether, dried over sodium sulfate and evaporated. Flash chromatography (SiO_2 , hexane/ethyl acetate - 4:1) yielded 0.8 of a colourless oil.

30 The colourless oil was dissolved in 13 ml of benzene and added to a solution of 1.3 g of Burgess-reagent (methoxycarbonylsulfamoyl-triethylammonium hydroxide, inner salt) in 40 ml of benzene. The reaction mixture was heated to 60°C for 3 hours. After distilling off most of the solvent, the residue was dissolved in ice water and
35 extracted with ether. The residue obtained after drying and evaporation of the solvent was purified by flash chromatography (SiO_2 , hexane/ethyl acetate = 9:1) to give 0.7 g of a slightly yellow oil.



This yellow oil was dissolved in 18 ml of ethanol and treated with a solution of 0.78 g of potassium hydroxide in 4 ml of water at 45°C for 2.5 hours. The reaction mixture was poured onto ice/saturated ammonium chloride solution, extracted with ether, dried
5 and evaporated. The residue was purified with medium pressure liquid chromatography (SiO₂, hexane/ethyl acetate = 9:1) to give 0.46 g of a slightly yellow oil. This yellow oil was dissolved in 20 ml of methylene chloride and treated with 1.6 g of manganese dioxide for 15 hours under vigorous stirring at room temperature. The
10 manganese dioxide was filtered off, the filtrate evaporated and the residue purified with medium pressure chromatography (SiO₂, hexane/2 % ethyl acetate) to give 225 mg of 2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-benzaldehyde as yellow oil which solidified in the cold.

15

85 mg of sodium hydride (50% in mineral oil) was washed with pentane and suspended in 4 ml of tetrahydrofuran. 470 mg of 4-(diethoxyphosphonyl)-3-methyl-but-2-enoic acid ethyl ester dissolved in 4 ml of tetrahydrofuran was added dropwise at 0°C, and
20 the reaction mixture was stirred at room temperature for 1 hour. After recooling to 0°C, a solution of 225 mg of the yellow aldehyde from the previous step in 3 ml of tetrahydrofuran was dropped in. The reaction mixture was stirred at room temperature for 3 hours, poured onto ice/saturated ammonium chloride solution, extracted
25 with ether, washed with water, dried and evaporated. The residue was purified first with flash chromatography (SiO₂, hexane/5% ethyl acetate) and then with medium pressure liquid chromatography (SiO₂, hexane/2% ethyl acetate) to give 229 mg of (2E,4E)-3-methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-phenyl]-penta-2,4-dienoic
30 acid ethyl ester as a colourless oil.


Example 18

Under the influence of retinoids, HL-60 cells (a human myeloid
35 leukemia cell line) differentiate into granulocytes. This differentiation of HL-60 cells into granulocytes is mediated by RAR α , and so provides the basis for the use of retinoids to treat leukemia. The results of this test demonstrate that the RXR-selective compounds of the invention,



at doses where they are inactive by themselves, are able to potentiate by up to an order of magnitude the pro-differentiating effects of all-trans retinoic acid and another RAR α -selective retinoid having the following formula:

5



(Compound A)

The ability of the test compounds to transactivate the retinoid receptors are as follows:

10

Table 1

	Activation (ED ₅₀ , nM)	
	RAR α	RXR α
All-trans retinoic acid	6.7	41
Compound A	3	> 10,000
Compound of Example 4	>10000	1.7

HL-60 Differentiation

15


Retinoid-induced differentiation of HL-60 cells was assayed by measuring their oxidative burst potential via the reduction of NBT (Nitroblueterstazolium) [Pick et al., *J. Reticuloendothelial Soc.*, **30**:581-593 (1981)].

20

HL-60 cells were maintained in RPMI 1640 medium supplemented with 10% FCS, 2mM L-glutamine, 1mM sodium pyruvate, 1% non-essential amino acids, 50 U/ml penicillin and 50 μ g/ml streptomycin (=RPMI/FCS). The cells were found to be free of mycoplasma.

25

30,000 cells/100 μ l of RPMI/FCS were seeded into flat-bottomed microtiter wells. 10 μ l of retinoids diluted in complete medium were



added at the same time to yield final concentrations between 10^{-11} and 10^{-6} M (stock solutions of 10^{-2} M in ethanol were kept at -20°C and protected from light). After 3 days, the medium was removed with a multichannel pipette and replaced with 100 μl of NBT solution (1 mg/ml in PBS with 200 nM phorbol myristate acetate (PMA)). Following an additional hour incubation at 37°C the NBT solution was removed and 100 μl of 10% SDS in 0.01 N HCl was added. The amount of the reduced NBT was quantified photometrically at 540 nm using an automated plate reader. The mean of 3 wells was calculated. S.E.M. were between 5 and 10%.

Results

Effects of RXR-selective retinoids on HL-60 differentiation

In agreement with its weak potency as an activator of $\text{RAR}\alpha$, the Example 4 RXR-selective retinoid was clearly less active as an inducer of HL-60 differentiation than all-trans retinoic acid (Fig. 1). Indeed, Example 4 was virtually inactive even at 1×10^{-6} M, in good agreement with its transactivation characteristics. HL-60 cells appear to be about 10x more sensitive to retinoids than the transactivation system (compare Table 1, $\text{RAR}\alpha$ and Fig. 1).

However, as can be seen from Figs. 2 and 3, the Example 4 RXR-selective retinoid was able to potentiate the effects of all-trans retinoic acid and Compound A at concentrations where it was not active by itself. The potentiation was in the range of 3x to 10x, i.e., 3 to 10 times higher concentrations of all-trans retinoic acid or Compound A alone are required to obtain comparable levels of HL-60 differentiation.

From the results obtained it is obvious that the effects of RXR-selective ligands on HL-60 differentiation are more than additive and can therefore not be explained by residual RAR -activating effects. The observed effects are also somewhat more pronounced if a preferential $\text{RAR}\alpha$ ligand (Compound A) rather than the less selective (RAR vs. RXR) all-trans RA is used. A potentiating effect is also compatible with *in vitro* data showing that RXR forms heterodimers



with RAR which leads to an enhanced transcriptional activity on RAR-specific promoter sequences. It is not clear at the moment why relatively high concentrations of RXR-selective retinoids (10^{-7} M) are required to see any effects. These concentrations are above two
5 orders of magnitude higher than the EC₅₀ in the RXR transcription activation assay, but it is not known whether the retinoid binding affinity of RXR changes upon heterodimer formation. Thus, ED₅₀ values as shown in Table 1 might not be fully representative for effects mediated through heterodimers involving RXR.

10

Example 19

The compound of Example 4 was tested for its ability to inhibit mouse B cell proliferation in combination with all-trans RA. The RXR
15 selective ligand of the invention potentiated the inhibitory activity of all-trans RA on mouse B cell proliferation.

Materials and Methods

20 Retinoids

The binding and transactivation characteristics of the retinoids used in these studies are shown in the following table:

25

Table 2

Retinoid	RAR α binding IC ₅₀ (nM)	RAR α activation ED ₅₀ (nM)	RXR α binding IC ₅₀ (nM)	RXR α activation ED ₅₀ (nM)
All-trans RA	14	6.7	>10,000	41
Compound of Example 4	> 10,000	>10,000	92	1.7

Cellular assays

30

Single cell suspensions of mouse spleen were set up in culture in flatbottomed 96 well Microtiter trays, 0.2 ml/well of a 2×10^5 /ml cell suspension in IMDM supplemented with 10% foetal calf serum, HEPES,



antibiotics and 50 μ M 2-mercaptoethanol. The specific B cell mitogen *E. coli* lipopolysaccharide (DIFCO) (LPS) was added at 50 μ g/ml. Cultures were incubated at 37°C in a humidified atmosphere and 5% CO₂.

5

The retinoids to be tested were first titrated in triplicate from 10 nM to 10 μ M and left throughout the whole culture period.

Subsequently, the active compounds were further titrated to reach the IC₅₀ values. Cyclosporin A (Sandoz AG) was used as a reference

10 compound (from 1 nM to 1 μ M).

After 2, 3 and 4 days of culture, the cells were pulsed with [³H] thymidine, 1 μ Ci/well for 4 hours. The cultures were then harvested on glass fiber filters and the radioactivity incorporated into DNA
15 measured in a β -liquid scintillation counter (Betaplate, Wallac Oy, Turku, Finland).

The results are expressed as % of the response of untreated cultures. Mitogen-induced proliferation was measured as
20 incorporation of ³H-thymidine after 24, 48 and 72 hours of culture. Retinoids were added to the cultures at the beginning of the culture period.


Results

25

1. Effect of RXR selective ligands on mouse B cell proliferation

The RXR selective ligand of Example 4 was tested first for direct interference with LPS induced mouse B cell proliferation. The results
30 are shown in Figure 4 and demonstrate that the Example 4 retinoid is inhibitory, with an IC₅₀ of 100 nM. This potency is 1/100 of that of all-*trans* RA (IC₅₀ =1 nM). At day 4, Example 4 retinoid at low doses ($\approx$ IC₅₀ at day 3) is slightly enhancing the response, which is consistent with the results of all retinoids active in this system.

35



2. RXR selective ligands potentiate the inhibitory effect of all-trans retinoic acid on mouse B cell proliferation

All-trans RA inhibits LPS induced mouse B cell proliferation with an IC₅₀ of 1 nM. Maximal inhibition is obtained with 10-30 nM and never exceeds 75-80%. The Example 4 RXR selective ligand of the invention was dosed into LPS stimulated cultures exposed to 1 nM of all-trans RA; cultures exposed to 10 nM of all-trans RA were set up in parallel. In all cases, concentrations of the Example 4 RXR ligand of the invention which are *per se* barely inhibitory induced a potentiation of the effect of 1 nM RA to the level observed with 10 nM RA. Similar results were obtained at day 2 and 3 of culture. The data of day 3 are as shown in Figure 5.

Because of the activity of the compound of Example 4, the effect is possibly an additive or enhancing. The results obtained at later points in culture, however, indicate that the effect is not simply additive, but rather an enhancement.

At day 4, 1 nM RA is not inhibitory any longer and actually induces a minor enhancement of the response, while 10 nM RA inhibits only about 30%. The reasons for this phenomenon are unknown, but the half life of the compound might play a role in it. The RXR selective ligand also has a similar effect (see curve of Figure 4). However, the *combination* of 1 nM RA and the Example 4 RXR ligand of the invention still results in an inhibition on the order of that induced by 10 nM RA. The results are shown in Figure 6.

The results demonstrate that an RXR selective retinoid (Example 4) potentiates the effect of all-trans RA in a functional system in which the retinoid effect is mediated by RAR α . Potentiation is obtained with a 10 to 30 fold excess RXR ligand over all-trans RA. The magnitude of the potentiation is roughly tenfold: the level of inhibition usually induced by 10 nM RA is obtained with 1 nM RA in combination with the RXR ligand of the invention.



Example 20

The following determinations using conventional assays of anti-acne activity demonstrate the anti-acne activity of compounds of the invention:

(1) Antiproliferative Activity on Human Sebocytes

Methods

10

Sebaceous cells were isolated from adult human sebaceous glands by a combination of enzymatic and mechanical methods (Doran et al., 1991). The cells were cultured in Iscove's medium containing 10% fetal calf serum and 4 $\mu\text{g/ml}$ dexamethasone on a layer of growth-arrested 3T3 mouse fibroblasts. Cells were plated in medium without the test compound and then given test compound in fresh medium 24-48 hours after the initial plating. The cultures were given fresh medium, containing the test compound, every 48 hours. On the day of harvesting, the cultures were rinsed with 0.03% EDTA in PBS, to remove only the 3T3 fibroblasts, followed by incubation in 0.05% trypsin/0.03% EDTA. The cells were suspended, mixed vigorously to prepare a single cell suspension and counted in a hemocytometer.

Stock solutions of compounds were made up as 10^{-2} M solutions in 100% DMSO and stored at -20°C in the dark. Compounds in solution were brought to room temperature and used by diluting directly into complete medium to the appropriate concentration.

The compounds were tested for the inhibition of proliferation of sebaceous cell growth *in vitro* at 10^{-6} and 10^{-7} M.

The compounds of Example 12, Example 2, and Example 4 were tested for their effects on inhibiting the proliferation of first passage human sebaceous cells *in vitro* after 10 days of exposure to drug. Results are reported as the concentration, in nM, required to inhibit growth by 50% (IC_{50}).

Table 3Inhibition of Human Sebaceous Cell Proliferation *In Vitro*

Compound	IC ₅₀ (nM)
Example 4	>1000 (tested twice)
Example 2	100 and 1000 (tested twice)
Example 12	100 (tested twice)
13-cis-retinoic acid	100
9-cis-retinoic acid	100

5

Example 4 compound displayed a poor dose response curve with suppression of growth reaching 30-40%. Although this is much weaker than 13-cis-retinoic acid, it is still indicative of biological activity *in vitro*. Example 2 compound gave an IC₅₀ of 100 nM for the first
10 experiment although a 1000 nM dose only gave a 70 % inhibition of growth in that experiment.

(2) Rhino Mouse Utricle Reduction Activity

15

In this model compounds are examined for their ability to reduce the size of pre-existing utricles, keratinized pilosebaceous structures which resemble human comedones (Mezick et al., 1985).

Method

20

Female Rhino mice (hr^{rh} hr^{rh}), 6 to 8 weeks of age, obtained from Jackson Laboratories, were used in groups of 6. Compounds were dissolved in 100% acetone and stored at 4°C for the duration of the experiment under nitrogen. The test compounds were applied to the
25 dorsa of the mice daily for 5 days for 3 consecutive weeks. One day after the last dose, the mice were sacrificed by CO₂ inhalation. A flap of skin from the dorsum was cut out and incubated in 2M sodium bromide for 2-3 hours at room temperature. The epidermis was then separated from the dermis.

30

The epidermis was then dehydrated through 70%, 80%, 95%, 100% ethanol, and xylene. The samples were kept in each of the above solutions for 2 hours. The skin samples were removed from the xylene



and mounted on glass microscope slides. Image analysis, using the Ultimage image analysis software, was used to determine the mean diameter and area of utricles. Approximately 5 fields per sample were examined, for an average of 150 utricles per mouse measured.

5

Results

Several compounds of the invention (Example 12, Example 2, and Example 4) were tested topically in the rhino mouse.

10

The mice were dosed topically with 100 μ l of 13-cis retinoic acid, 9-cis retinoic acid, and the compounds of Example 12, Example 2, and Example 4 in acetone. The results are shown in Table 4, below:

15



Table 4

Compound	Dose ($\mu\text{g/day}$)	Utricle Size (μm^2 / utricle)	% Change from Control
Vehicle		9750 $\pm$ 508	---
13-cis-RA	0.1	9187 $\pm$ 794	-6 ^{ns}
	1	6400 $\pm$ 424	-34
	10	3793 $\pm$ 368	-61
	100	3132 $\pm$ 305	-68
9-cis-RA	0.1	8650 $\pm$ 427	-11
	1	6926 $\pm$ 497	-29
	10	3540 $\pm$ 354	-64
	100	2644 $\pm$ 312	-73
Example 12	0.1	9104 $\pm$ 829	-7 ^{ns}
	1	9156 $\pm$ 938	-6 ^{ns}
	10	7634 $\pm$ 485	-22
	100	3596 $\pm$ 300	-63
Example 2	0.1	9535 $\pm$ 890	-2 ^{ns}
	1	9616 $\pm$ 1134	-1 ^{ns}
	10	9049 $\pm$ 891	-7 ^{ns}
	100	5437 $\pm$ 615	-44
Example 4	0.1	9843 $\pm$ 565	+1 ^{ns}
	1	9491 $\pm$ 507	-3 ^{ns}
	10	8951 $\pm$ 964	-8 ^{ns}
	100	5916 $\pm$ 992	-39

5 ns = not statistically significant from controls, all other p values <0.05.



NOTES:

During this experiment several side effects were noticed. The 100 µg 13-cis-retinoic acid-dosed animals displayed exfoliation and erythema on day 5. The 9-cis-retinoic acid-dosed animals showed these effects a day earlier at the same dose.

On day 7 of dosing, erythema was seen for 100 µg Example 12. There was some erythema noticed on the 100 µg Example 2 animals on the same day. However, the erythema was not as intense as that for Example 12. At this same time point, the comparable dose of Example 4 showed no appreciable erythema.

By the 14th day of dosing there was exfoliation seen on all 100 µg Example 12-dosed animals which was not seen the day before. If the compounds are rank-ordered for the 100 µg concentration with respect to exfoliation/erythema from most severe to least severe, the order would be: 9-cis-RA, 13-cis-RA, Example 12, Example 2, and Example 4.

Thus, the compounds of the invention produced reduced irritation in comparison to 9-cis-RA, 13-cis-RA.

(3) *In vivo* Effect of Compounds on the Size of Sebaceous Glands of Golden Syrian Hamsters

Methods

Charles River Golden Syrian male hamsters were given the desired dose in acetone. The compounds were stored at 4°C protected from light. Fresh solutions were made up weekly.

Hamsters were dosed daily for five days, rested for two days, and dosed again for five days until 20 doses were given. The volume of solution was 50 microliters per ear.

Hamsters were sacrificed by CO₂ inhalation, and the ears removed for histological evaluation. One ear was removed and the



ventral surface separated from the rest of the ear. A 2 mm punch was removed 5 mm from the tip of the ear and stained in 0.1 % Sudan Black B dissolved in 100 % propylene glycol overnight. After destaining, the size of sebaceous glands was quantified with a

5 Donsanto Image Analysis System.

Data are given as the average area of 80-120 sebaceous glands per dose, as percent of the control (solvent-treated) sections.

10 Table 5

Effect of 4 Weeks Topical Dosing with the compound of Example 4 and 13-cis-retinoic acid on Hamster Ear Sebaceous Gland Size

15

Compound	Dose ($\mu\text{g/day}$)	Sebaceous Gland Size	% Change from Control
Vehicle	---	16475 $\pm$ 1708	---
13-cis-RA	1	14029 $\pm$ 2977	-15 ^{ns}
	10	12965 $\pm$ 2029	-21
	100	10459 $\pm$ 1302	-37
Example 4	1	13237 $\pm$ 1491	-20
	10	17046 $\pm$ 4667	+3 ^{ns}
	100	13043 $\pm$ 1577	-21

ns = not statistically significant from controls. All other values significant from vehicle controls.

20

References

Doran et al., "Characterization of human sebaceous cells *in vitro.*, *J. Invest. Dermatol.*, 96:341-348 (1991).

25




Mezick et al., "Topical and systemic effects of retinoids on horn-filled utriculus size in the rhino mouse. A model to quantify 'antikeratinizing' effects of retinoids.", *J. Invest. Dermatol.*, **83**:110-113 (1985).

5

Example 21


The compound of Example 6 was tested for its ability to inhibit a human breast carcinoma cell line in combination with a retinoid having RAR α activity, all-E-3,7-dimethyl-9-[(2-methoxy-4-methyl-6-octyloxy)phenyl]-2,4,6,8-nonatetraenoic acid (Compound B), as shown:



Compound B

The results demonstrated that the RXR selective ligand of the invention potentiated the solid tumor inhibitory activity of Compound B.


15



1. Synthesis of Compound B

Compound B was prepared in accordance with the following procedure:


5



A solution of 2,6-dihydroxy-4-methylbenzoic acid 1 in acetone (50.4 g; 750 ml) was treated with methyl iodide (100 ml) and potassium carbonate (124.2 g) and heated at reflux for 18 hours. The mixture was then cooled to room temperature and filtered free of solids. Concentration of the solution gave the crude product which was dissolved in ethylacetate and washed with aqueous sodium hydroxide solution (1N; cold). Removal of the solvents *in vacuo* then gave methyl 2,6-dimethoxy-4-methylbenzoate 2 (54 g). This material (52.5 g) was dissolved in dichloromethane (1000 ml) cooled to -70°C and treated with a solution of borontrichloride in the same solvent (29.3 g/100 ml; 180 ml). This mixture was then warmed up to room temperature and



stirred for a further 45 minutes and then poured onto ice. The organic layer was separated, washed with more water, dried (magnesium sulphate), filtered and concentrated. The residue was then purified by high performance preparative liquid chromatography (HPLC) using a Waters prep.500 chromatograph (7% ethyl acetate/hexane eluent) to give pure methyl 2-hydroxy-6-methoxy-4-methyl benzoate 3 as a solid (28.3 g). A solution of this material (35 g) in methyl ethyl ketone (700 ml) containing potassium carbonate (27.1 g) was treated with 1-octyliodide (34.2 g) and heated at reflux for 20 hours. The reaction mixture was cooled, filtered free of solids and the filtrate was concentrated and then redissolved in a mixture of hexane and ethyl acetate. This solution was then washed with aqueous base (1N sodium hydroxide), water, dried (magnesium sulphate) and concentrated to dryness. Purification by HPLC as before gave pure methyl 2-methoxy-6-octyloxy-4-methyl-benzoate 4 (51.8 g). A solution of this material (51.8 g) in toluene (500 ml) was cooled to -60°C and treated with a solution of diisobutylaluminum hydride (25% in hexane; 281 ml) and then warmed to room temperature. The reaction mixture was then carefully treated with aqueous methanol (100 ml; 1:1) with cooling so that the temperature was kept at 20°C followed by the addition of hexane (500 ml) and magnesium sulphate. The solids were then filtered off and the solvents were removed *in vacuo* to yield the crude alcohol 5. This material (47 g) was dissolved in acetonitrile (500 ml) containing triphenylphosphoniumhydrobromide (54.9 g) and heated at reflux for 22 hours. The solvents were then removed *in vacuo* and the crude salt 6 was dried at room temperature at 0.1 mm Hg pressure (this material can be crystallised from tetrahydrofuran to give pure [(2-methoxy-6-octyloxy-4-methyl)phenyl]methyl-triphenylphosphonium bromide). This salt 6 was then converted into Compound B, all-E-3,7-dimethyl-9-[(2-methoxy-4-methyl-6-octyloxy)phenyl]-2,4,6,8-nonatetraenoic acid, as described in U.S. Patent No. 4,894,480 (example 5).



2. Testing

Retinoid receptor binding and transactivation assays were performed on Compound B and Example 6 as described above. The results were as follows:

Table 6

Compound		Activation				Binding		
		RAR		RXR		RAR		RXR
		EC ₅₀ (nM)	%max	EC ₅₀ (nM)	%max	IC ₅₀ (nM)	%	IC ₅₀ (nM)
B	α	11	114	at 1000	0	240	--	
	β	5.3	82			500	--	
	γ	at 1000	48			>10,000	<20	
Ex. 6	α	at 1000	4	1.4	--	>10,000	24	110
	β	at 1000	8			>10,000	9	--
	γ	at 1000	9			>10,000	245	150

10

Breast carcinoma cell line, T47-D, obtained from the ATCC [Accession No. HTB133] was grown in RPMI 1640 media supplemented with 10% FBS, 10 µg/ml insulin and 13 ng/ml gentamicin, and incubated at 37°C, 4.5% CO₂ and 95.5% humidified air. The cells were harvested upon reaching 70-80% confluency and pelleted. The cells were resuspended in the media and seeded (150 µl/well) into 96-well plates (Corning) at a density allowing linear growth over a seven day assay period (i.e., T47-D seeded at 4 x 10³ cells/well). Plates were placed in an incubator at 37°C overnight.

20

Drugs (1 mM stock in 100% DMSO) were added 18-24 hours post-seeding. Drug combinations were prepared in 96-well microtiter plates and manually added to the assay plates. MTT assays were performed at days 3-7 post drug addition. The MTT assay is a tetrazolium-based assay which measures the viability of cells in culture. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) stock solution (5 mg/ml in 1x PBS) was added to assay plates (50 µl/well) and incubated for 2.5 hours at 37°C.

25



Liquid was removed by aspiration, 50 μ l 95% ethanol was added, and the plates were shaken (Mini-Orbital Shaker, Bellco) for 15 minutes to solubilize the formazan product. The optical density of each well was measured using an automatic plate reader (Microplate
5 EL320 Reader, Bio-Tek Instruments) with a test wavelength of 570 nm and a reference wavelength of 660 nm. The amount of cell growth inhibition caused by various concentrations of Compound B in combination with a constant concentration of the compound of Example 6 was determined in accordance with the following equation:

$$\% \text{ Inhibition} = \frac{\text{OD}_{570} \text{ (untreated)} - \text{OD}_{570} \text{ (drug treated)}}{\text{OD}_{570} \text{ (untreated)}} \times 100$$

10

The results are shown graphically in Figure 7. The results demonstrate that the RXR-selective compound of the invention potentiates the activity of a retinoid having RAR α activity in inhibiting
15 the growth of a solid tumor cell line.

EXAMPLE A

Hard Gelatine capsules containing 20 mg. active substance:

20 Composition: One Capsule contains:

	Formula I	20 mg.
	RAR α retinoid	20 mg
	Gelatine Bloom 30	70.0 mg.
25	Maltodextrin MD 05	108.0 mg.
	dl- α -Tocopherol	2.0 mg.
	Sodium ascorbate	10.0 mg.
	Microcrystalline cellulose	48.0 mg.
	Magnesium stearate	2.0 mg.
30	(weight capsule content)	280.0 mg.



Procedure:

The active substances are wet milled in a solution of gelatine, maltodextrin, dl- α -Tocopherol and sodium ascorbate.

5

The wet milled suspension is spray-dried

The spray-dried powder is mixed with microcrystalline cellulose and magnesium stearate.

10

280 mg. each of this mixture are filled into hard gelatine capsules of suitable size and color.



- Figure 1: Induction of differentiation of HL-60 cells with all-trans retinoic acid (RA), another RAR α -selective retinoid (compound A, herein), and an RXR-selective retinoid (Example 4, herein).
- 5
- Figure 2: Induction of differentiation of HL-60 cells with combinations of all-trans retinoic acid (RA) and Example 4.
- 10
- Figure 3: Induction of differentiation of HL-60 cells with combinations of compound A and Example 4.
- Figure 4: Thymidine incorporation by B cell cultures exposed to all-trans RA or Example 4.
- 15
- Figure 5: Inhibition of LPS-induced B cell proliferation by all-trans RA and Example 4, alone and in combination, at day 3 of culture.
- 20
- Figure 6: Inhibition of LPS-induced B cell proliferation by all-trans RA and Example 4, alone and in combination, at day 4 of culture.
- 25
- Figure 7: Enhanced antiproliferative activity of a compound having RAR α activity (Compound B) and an RXR-selective compound (Example 6) in a breast cancer cell line.





Fig. 1 Induction of differentiation of HL-60 cells with all-trans RA, Compound A, an RAR α -selective retinoid, and Example 4, an RXR-selective retinoid. OD₅₄₀ is proportional to the number of differentiated HL-60 cells.



Combination of All-trans RA with an RXR-selective retinoid




Fig. 2 Induction of HL-60 differentiation with combinations of all-trans RA and Ex. 4 RXR selective retinoid.

Combination of Compound A with an RXR-selective retinoid




Fig. 3 Induction of HL-60 differentiation with combinations of Compound A and Ex. 4 RXR selective retinoid.

This Sheet Has Been Replaced





Figure 4. Thymidine incorporation by cultures exposed to *all-trans* RA or to Example 4 RXR-selective retinoid. Values are relative to untreated cultures.

This Sheet Has Been Replaced




Figure 5. Inhibition of LPS induced B cell proliferation by RA and Example 4 RXR selective retinoid alone or in combination. Results at day 3 of culture





Figure 6. Inhibition of LPS induced B cell proliferation by RA and Example 4 RXR selective retinoid alone or in combination. Results at day 4 of culture


This Sheet Has Been Replaced



Figure 7


Enhanced antiproliferative activity of a compound having RAR-alpha activity (compound B) and a RXR-selective compound (example 6) in a breast cancer cell line





Claims

1. A compound of the formula:



5

- wherein the C₇-C₈ bond is a double bond or triple bond, R₁ and R₂ are independently halogen or lower alkyl when the C₇-C₈ bond is a double bond or R₁ and R₂ are independently lower alkyl when the C₇-C₈ bond is a triple bond, or R₁ and R₂ taken together are C₃₋₁₃-alkylene in which one carbon atom may be substituted by a heteroatom selected from the group consisting of sulfur, oxygen and nitrogen, or R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring having from 5-6 carbon atoms or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur and the remaining atoms of R₁ and R₂ are carbon, and the pharmaceutically acceptable salts, esters and amides.

- 20 2. A compound of claim 1 wherein the C₇-C₈ bond is a double bond.

3. The compound of claim 2 wherein R₁ and R₂ taken together are C₃₋₆-alkylene in which one carbon atom may be substituted by a heteroatom selected from the group consisting of sulfur, oxygen and nitrogen.

4. A compound of claim 3 wherein R₁ and R₂ taken together are C₃₋₆-alkylene.





5. The compound of claim 4,

(2E,4E)-3-Methyl-5-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclopenten-1-yl)-2,4-pentadienoic acid,

(2E,4E)-3-methyl-5-(2-(2-((E)-2-(2,6,6-trimethyl-1-cyclohex-
5 1-yl)ethenyl)-1-cyclohexen-1-yl)-2,4-pentadienoic acid,

(2E,4E)-3-methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cyclohepten-1-yl)-2,4-pentadienoic acid and

(2E,4E)-3-Methyl-5-(2-((E)-2(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-1-cycloocten-1-yl)-2,4-pentadienoic acid.

10 6. A compound of claim 2 wherein R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring having from 5-6 carbon atoms or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur and the remaining
15 atoms of R₁ and R₂ are carbon.

7. The compound of claim 6,

(2E,4E)-3-methyl-5-(2-(2-((E)-2-(2,6,6-trimethyl-1-cyclohex-1-yl)ethenyl)-1-phenyl)-2,4-pentadienoic acid,

(2E,4E)-3-Methyl-5-(2-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-
20 yl)ethenyl)-3-thienyl)-2,4-pentadienoic acid,

(2E,4E)-3-methyl-5-(3-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-2-thienyl)-2,4-pentadienoic acid and

(2E,4E)-3-Methyl-5-(4-((E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl)-3-thienyl)-2,4-pentadienoic acid.

25 8. A compound of claim 2 wherein R₁ and R₂ are lower alkyl which may be the same or different.

9. The compound of claim 8,

(2E,4E,6Z,8E)-3,6,7-trimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid.

30

10. The compound of claim 2 wherein one of R₁ and R₂ is lower alkyl and the other is halogen.





11. The compound of claim 10,

(all-E)-6-bromo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid,

5 (all-E)-6-chloro-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid and

(all-E)-6-iodo-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid.

12. A compound of claim 1 wherein the C₇-C₈ bond is a triple
10 bond.

13. A compound of claim 12 wherein R₁ and R₂ taken together are C₃₋₁₃-alkylene in which one carbon atom may be substituted by a heteroatom selected from the group consisting of sulfur, oxygen and nitrogen, or R₁ and R₂ taken together with the carbon atoms to which
15 they are attached are an aromatic ring having from 5-6 carbon atoms or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur and the remaining atoms of R₁ and R₂ are carbon.

14. A compound of claim 23 wherein R₁ and R₂ taken together
20 are C₃₋₆-alkylene.

15. The compounds of claim 14

(2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclopent-1-enyl]-penta-2,4-dienoic acid and

25 (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-cyclohept-1-enyl]-penta-2,4-dienoic acid.

16. A compound of claim 12 wherein R₁ and R₂ taken together with the carbon atoms to which they are attached are an aromatic ring having from 5-6 carbon atoms or a heteroaromatic ring having from 5-6 atoms in which one atom of R₁ or R₂ is a heteroatom selected from
30 the group consisting of oxygen, nitrogen and sulfur and the remaining atoms of R₁ and R₂ are carbon.


17. A compound of claim 16 wherein said ring is selected from the group consisting of thiophene, benzene and pyridine.





18. The compound of claim 17, (2E,4E)-3-Methyl-5-[2-(2,6,6-trimethyl-cyclohex-1-enylethynyl)-phenyl]-penta-2,4-dienoic acid.

19. A compound of the formula:



5

20. A pharmaceutical composition comprising a compound of formula I given in claim 1 or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable inert carrier.

21. A composition of claim 21 for topical administration
10 wherein said compound is present in said composition in an amount from about 0.05% to about 3% by weight of the total composition.

22. A composition in unit dosage form for oral administration comprising:

a first compound which is a retinoid having $RAR\alpha$ activity;

15 a second compound of the formula I given in claim 1 or a pharmaceutically acceptable salts, esters or amide thereof, wherein said first compound is present in said unit dosage form in an amount from 10 to 50 mg and said second compound is present in said unit dosage form in an amount from 1 to 10 times the amount of said first compound.

20 23. A compound as claimed in claim 1 for use a pharmaceutical, especially for the treatment of solid tumors, leukemia or acne.

24. The use of a compound as claimed in claim 1 for the manufacture of a pharmaceutical composition for the treatment of
25 solid tumors, leukemia or acne.

25. The invention as described hereinbefore, especially with reference to the Examples.

